Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

• 主要な著者: Dranitsaris G (著者), Shane LG (著者), Crowther M (著者), Feugere G (著者), Woodruff S (著者)
• フォーマット: 図書
• 出版事項: Dove Medical Press, 2017-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

George Dranitsaris,1 Lesley G Shane,2 Mark Crowther,3 Guillaume Feugere,4 Seth Woodruff2 1Health Economic and Outcomes Research, Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 2Pfizer Inc, New York, NY, USA; 3McMaster University, Hamilton, ON, 4Pfizer Canada, Montreal, QC, Canada Background:...